Judith A Gilbert. Show Affiliations »
Abstract
Entities: Chemical
Mesh： See more » Antineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useBiomarkers, Tumor/geneticsCarcinoma, Renal Cell/drug therapyCarcinoma, Renal Cell/geneticsCarcinoma, Renal Cell/mortalityCarcinoma, Renal Cell/pathologyClinical Trials, Phase II as TopicHumansKidney Neoplasms/drug therapyKidney Neoplasms/geneticsKidney Neoplasms/mortalityKidney Neoplasms/pathologyMulticenter Studies as TopicMutationProtein Kinase Inhibitors/adverse effectsProtein Kinase Inhibitors/therapeutic useProto-Oncogene Proteins c-met/antagonists & inhibitorsProto-Oncogene Proteins c-met/geneticsPyrazines/adverse effectsPyrazines/therapeutic useTreatment OutcomeTriazines/adverse effectsTriazines/therapeutic use
Substances： See more » Antineoplastic AgentsBiomarkers, TumorProtein Kinase InhibitorsPyrazinesTriazines1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazineMET protein, humanProto-Oncogene Proteins c-met
Year: 2017 PMID： 28669737 DOI： 10.1016/S1470-2045(17)30508-9
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316